Jason Lewis, Ph.D.

A new radiotheranostic system has the ability to detect and treat ovarian cancer noninvasively, according to new research published in the April issue of The Journal of Nuclear Medicine. Combining the highly specific huAR9.6 antibody with PET and therapeutic radionuclides, this theranostic platform may provide more personalized treatment to improve health outcomes for ovarian cancer patients.

Ovarian cancer causes more deaths than any other gynecologic malignancy, with a five-year survival rate below 30 percent for patients diagnosed at advanced stages. The current standard of care for ovarian cancer consists of surgery followed by platinum-based chemotherapy; however, these methods have failed to increase overall survival rates in patients because of tumor recurrence and chemoresistance… Continue reading.

WASHINGTON, D.C. — The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of Jason Lewis, Ph.D., Professor and Vice Chair, Radiology and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center to its College of Fellows. Dr. Lewis was nominated, reviewed, and elected by peers and members of the AIMBE College of Fellows for his groundbreaking work in radiochemistry and molecular imaging and on the clinical translation of novel oncological imaging agents.

The College of Fellows is comprised of the top two percent of medical and biological engineers in the country. The most accomplished and distinguished engineering and medical school chairs, research directors, professors, innovators, and successful entrepreneurs comprise the College of Fellows. AIMBE Fellows are regularly recognized for their contributions in teaching, research, and innovation. AIMBE Fellows have been awarded the Nobel Prize, the Presidential Medal of Science and the Presidential Medal of Technology and Innovation, and many also are members of the National Academy of Engineering, National Academy of Medicine, and the National Academy of Sciences… Continue reading.